FRANCISCO CARLOS DA COSTA DARRIEUX

(Fonte: Lattes)
Índice h a partir de 2011
15
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Mostrar mais
Limpar filtros

Configurações

Colaboração internacional: Estados Unidos ×

Resultados de Busca

Agora exibindo 1 - 10 de 10
  • article 32 Citação(ões) na Scopus
    Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
    (2018) VERONESE, Pedro; HACHUL, Denise Tessariol; SCANAVACCA, Mauricio Ibrahim; HAJJAR, Ludhmila Abrahao; WU, Tan Chen; SACILOTTO, Luciana; VERONESE, Carolina; DARRIEUX, Francisco Carlos da Costa
    Aim Acute and subacute cardiotoxicity are characterized by prolongation of the corrected QT interval (QTc) and other measures derived from the QTc interval, such as QTc dispersion (QTdc) and transmural dispersion of repolarization (DTpTe). Although anthracyclines prolong the QTc interval, it is unclear whether breast cancer patients who undergo the ACT chemotherapy regimen of anthracycline (doxorubicin: A), cyclophosphamide (C) and taxane (T) may present with QTc, QTdc and DTpTe prolongation. Methods Twenty-three consecutive patients with breast cancer were followed prospectively during ACT chemotherapy and were analyzed according to their QT measurements. QTc, QTdc and DTpTe measurements were determined by a 12-lead electrocardiogram (EKG) prior to chemotherapy (baseline), immediately after the first phase of anthracycline and cyclophosphamide (AC) treatment, and immediately after T treatment. Serum troponin and B-type natriuretic peptide (BNP) levels were also measured. Results Compared to baseline values, the QTc interval was significantly prolonged after the AC phase (439.7 +/- 33.2 ms vs. 472.5 +/- 36.3 ms, p = 0.001) and after T treatment (439.7 +/- 33.2 ms vs. 467.9 +/- 42.6 ms, p < 0.001). Troponin levels were elevated after the AC phase (23.0 pg/mL [min-max: 6.0-85.0] vs. 6.0 pg/mL [min-max: 6.0-22.0], p < 0.001) and after T treatment (25.0 pg/mL [min-max: 6.0-80.0] vs. 6.0 pg/mL [min-max: 6.0-22.0], p < 0.001) compared to baseline values. Conclusion In this prospective study of patients with non-metastatic breast cancer who underwent ACT chemotherapy, significant QTc prolongation and an elevation in serum troponin levels were observed.
  • article 15 Citação(ões) na Scopus
    European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?
    (2018) DAGRES, Nikolaos; CHAO, Tze-Fan; FENELON, Guilherme; AGUINAGA, Luis; BENHAYON, Daniel; BENJAMIN, Emelia J.; BUNCH, T. Jared; CHEN, Lin Yee; CHEN, Shih-Ann; DARRIEUX, Francisco; PAOLA, Angelo de; FAUCHIER, Laurent; GOETTE, Andreas; KALMAN, Jonathan; KALRA, Lalit; KIM, Young-Hoon; LANE, Deirdre A.; LIP, Gregory Y. H.; LUBITZ, Steven A.; MARQUEZ, Manlio F.; POTPARA, Tatjana; POZZER, Domingo Luis; RUSKIN, Jeremy N.; SAVELIEVA, Irina; TEO, Wee Siong; TSE, Hung-Fat; VERMA, Atul; ZHANG, Shu; CHUNG, Mina K.
  • article 0 Citação(ões) na Scopus
    Transient ascending ST-segment depression and widening of the S wave in 3-channel Holter monitoring-A sign of dromotropic disturbance in the right ventricular outflow tract in the Brugada syndrome: A report of five cases
    (2022) ANDRADE, Antonio Thomaz de; BARBOSA-BARROS, Raimundo; NIKUS, Kjell; RAIMUNDO, Rodrigo D.; ABREU, Luiz C. de; SACILOTTO, Luciana; DARRIUEX, Francisco C. C.; YANOWITZ, Frank G.; BRUGADA, Pedro; PEREZ-RIERA, Andres Ricardo
    Background Brugada syndrome (BrS) is somewhat a challenging diagnosis, due to its dynamic pattern. One of the aspects of this disease is a significant conduction disorder located in the right ventricular outflow tract (RVOT), which can be explained as a consequence of low expression of Connexin-43. This decreased conduction speed is responsible for the typical electrocardiographic pattern. Opposite leads located preferably in inferior leads of the electrocardiogram may show a deep and widened S wave associated with ascending ST segment depression. Holter monitoring electrocardiographic (ECG) aspects is still a new frontier of knowledge in BrS, especially in intermittent clinical presentations. Methods We describe, as an exploratory analysis, five case series of intermittent type 1 BrS to demonstrate the appearance of ascending ST segment depression and widening of the S wave, during 3-channel 24h-Holter monitoring (C1, C2 and C3) with bipolar leads. Results In the five cases described, the ST segment depression was observed mainly in C2, but in some cases also in C1 and C3. Only case 1 presented concomitant intermittent elevation of the ST segment in C1. All cases were intermittent. Conclusion The recognition of an ECG pattern with ascending ST-segment depression and widening of the S wave in 3-channel Holter described in this case series should raise a suspicion of the BrS and suggests the counterpart of a dromotropic disturbance registered in the RVOT and/or reciprocal changes.
  • article 25 Citação(ões) na Scopus
    Percutaneous Transatrial Access to the Pericardial Space for Epicardial Mapping and Ablation
    (2011) SCANAVACCA, Mauricio I.; VENANCIO, Ana Claudia; PISANI, Cristiano F.; LARA, Sissy; HACHUL, Denise; DARRIEUX, Francisco; HARDY, Carina; PAOLA, Edna; AIELLO, Vera D.; MAHAPATRA, Srijoy; SOSA, Eduardo
    Background-Puncture of the atrial appendage may provide access to the pericardial space. The aim of this study was to evaluate the feasibility of epicardial mapping and ablation through an endocardial transatrial access in a swine model. Methods and Results-An 8-F Mullins sheath was used to perforate the right (n=16) or left (n=1) atrial appendage in 17 pigs (median weight, 27.5 kg; first and third quartiles [Q1, Q3], 25.2, 30.0 kg). A 7-F ablation catheter was introduced into the pericardial space to perform epicardial mapping and deliver radiofrequency pulses on the atria. The pericardial space was entered in all 17 animals. In 15 (88%) animals, there was no hemodynamic instability (mean blood pressure monitoring, initial median, 80 mm Hg; Q1, Q3, 70, 86 mm Hg; final median, 88 mm Hg; Q1, Q3, 80, 96 mm Hg; P=0.426). In these 15, a mild hemorrhagic pericardial effusion was identified and aspirated (median, 20 mL; Q1, Q3, 15, 30 mL) during the procedure, and postmortem gross analysis revealed that the atrial perforation was closed in these animals. In 2 (12%) of the 17 animals, there was major pericardial bleeding with hemodynamic collapse. On gross examination, it was found that pericardial space was accessed through right ventricular perforation in 1 animal and the tricuspid annulus in the other. After the initial study, we used an occlusion device in 3 other animals to attempt to seal the puncture (2 at the right atrial appendage and 1 at the right ventricle). These 3 animals had no significant pericardial bleeding. Conclusions-Transatrial endovascular right atrial appendage puncture may provide a potential alternative route for pericardial access. Further studies are needed to evaluate its safety with longer and more-complex procedures before being applied in clinical settings. (Circ Arrhythm Electrophysiol. 2011;4:331-336.)
  • article 22 Citação(ões) na Scopus
    Efficacy and safety of combined endocardial/epicardial catheter ablation for ventricular tachycardia in Chagas disease: A randomized controlled study
    (2020) PISANI, Cristiano F.; ROMERO, Jorge; LARA, Sissy; HARDY, Carina; CHOKR, Muhieddine; SACILOTTO, Luciana; WU, Tan Chen; DARRIEUX, Francisco; HACHUL, Denise; KALIL-FILHO, Roberto; BIASE, Luigi Di; SCANAVACCA, Mauricio
    BACKGROUND Epicardial mapping and ablation are frequently necessary to eliminate ventricular tachycardia (VT) in patients with Chagas disease. Nonetheless, there are no randomized controlled trials demonstrating the role of this strategy. OBJECTIVE We conducted this randomized controlled trial to evaluate the efficacy and safety of combined epicardial ablation in patients with Chagas disease. METHODS We randomized patients with Chagas disease and VT in a 1:1 fashion to either the endocardial (endo) mapping and ablation group or the combined endocardial/epicardial (endo/epi) mapping and ablation group. The efficacy end points were measured by VT inducibility and all-ventricular arrhythmia recurrence. Safety was assessed by the rate of periprocedural complications. RESULTS Thirty patients were enrolled, and most were male. The median age was 67 (Q1: 58; Q3: 70) years in the endo group and 58 (Q1: 43; Q3: 66) years in the endo/epi group. The left ventricular ejection fraction was 33.0% +/- 9.5% and 35.2% +/- 11.5%, respectively P = .13. Acute success (non-reinducibility of clinical VT) was obtained in 13 patients (86%) in the endo/epi group and in 6 patients (40%) in the endo-only group (P = .021). There were 12 patients with VT recurrence (80%) in the endo-only group and 6 patients (40%) in the endo/epi group (P = .02) (by intention-to-treat analysis). Epicardial ablation was ultimately per formed in 9 patients (60%) in the endo-only group because of an absence of endocardial scar or maintenance of VT inducibility. There was no difference in complications between the groups. CONCLUSION Combining endo/epi VT catheter ablation in patients with Chagas disease significantly increases shortand long-term freedom from all-ventricular arrhythmias. Epicardial access did not increase periprocedural complication rates.
  • article 157 Citação(ões) na Scopus
    2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary
    (2019) TOWBIN, Jeffrey A.; MCKENNA, William J.; ABRAMS, Dominic J.; ACKERMAN, Michael J.; CALKINS, Hugh; DARRIEUX, Francisco C. C.; DAUBERT, James P.; CHILLOU, Christian de; DEPASQUALE, Eugene C.; DESAI, Milind Y.; III, N. A. Mark Estes; HUA, Wei; INDIK, Julia H.; INGLES, Jodie; JAMES, Cynthia A.; JOHN, Roy M.; JUDGE, Daniel P.; KEEGAN, Roberto; KRAHN, Andrew D.; LINK, Mark S.; MARCUS, Frank I.; MCLEOD, Christopher J.; MESTRONI, Luisa; PRIORI, Silvia G.; SAFFITZ, Jeffrey E.; SANATANI, Shubhayan; SHIMIZU, Wataru; TINTELEN, J. Peter van; WILDE, Arthur A. M.; ZAREBA, Wojciech
    Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right/left ventricular cardiomyopathy, cardiac amyloidosis, sarcoidosis, Chagas disease, and left ventricular noncompaction. The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. This expert consensus statement provides the clinician with guidance on evaluation and management of ACM and includes clinically relevant information on genetics and disease mechanisms. PICO questions were utilized to evaluate contemporary evidence and provide clinical guidance related to exercise in arrhythmogenic right ventricular cardiomyopathy. Recommendations were developed and approved by an expert writing group, after a systematic literature search with evidence tables, and discussion of their own clinical experience, to present the current knowledge in the field. Each recommendation is presented using the Class of Recommendation and Level of Evidence system formulated by the American College of Cardiology and the American Heart Association and is accompanied by references and explanatory text to provide essential context. The ongoing recognition of the genetic basis of ACM provides the opportunity to examine the diverse triggers and potential common pathway for the development of disease and arrhythmia.
  • article 23 Citação(ões) na Scopus
    European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases
    (2022) WILDE, Arthur A. M.; SEMSARIAN, Christopher; MARQUEZ, Manlio F.; SHAMLOO, Alireza Sepehri; ACKERMAN, Michael J.; ASHLEY, Euan A.; EDUARDO, Back Sternick; BARAJAS-MARTINEZ, Hector; BEHR, Elijah R.; BEZZINA, Connie R.; BRECKPOT, Jeroen; CHARRON, Philippe; CHOCKALINGAM, Priya; CROTTI, Lia; GOLLOB, Michael H.; LUBITZ, Steven; MAKITA, Naomasa; OHNO, Seiko; ORTIZ-GENGA, Martin; SACILOTTO, Luciana; SCHULZE-BAHR, Eric; SHIMIZU, Wataru; SOTOODEHNIA, Nona; TADROS, Rafik; WARE, James S.; WINLAW, David S.; KAUFMAN, Elizabeth S.; AIBA, Takeshi; BOLLMANN, Andreas; CHOI, Jong-Il; DALAL, Aarti; DARRIEUX, Francisco; GIUDICESSI, John; GUERCHICOFF, Mariana; HONG, Kui; KRAHN, Andrew D.; INTYRE, Ciorsti Mac; MACKALL, Judith A.; MONT, Lluis; NAPOLITANO, Carlo; JUAN, Pablo Ochoa; PEICHL, Petr; PEREIRA, Alexandre C.; SCHWARTZ, Peter J.; SKINNER, Jon; STELLBRINK, Christoph; TFELT-HANSEN, Jacob; DENEKE, Thomas
  • article 77 Citação(ões) na Scopus
    European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases
    (2022) WILDE, Arthur A. M.; SEMSARIAN, Christopher; MARQUEZ, Manlio F.; SHAMLOO, Alireza Sepehri; ACKERMAN, Michael J.; ASHLEY, Euan A.; STERNICK, Eduardo Back; BARAJAS-MARTINEZ, Hector; BEHR, Elijah R.; BEZZINA, Connie R.; BRECKPOT, Jeroen; CHARRON, Philippe; CHOCKALINGAM, Priya; CROTTI, Lia; GOLLOB, Michael H.; LUBITZ, Steven; MAKITA, Naomasa; OHNO, Seiko; ORTIZ-GENGA, Martin; SACILOTTO, Luciana; SCHULZE-BAHR, Eric; SHIMIZU, Wataru; SOTOODEHNIA, Nona; TADROS, Rafik; WARE, James S.; WINLAW, David S.; KAUFMAN, Elizabeth S.; AIBA, Takeshi; BOLLMANN, Andreas; CHOI, Jong-Il; DALAL, Aarti; DARRIEUX, Francisco; GIUDICESSI, John; GUERCHICOFF, Mariana; HONG, Kui; KRAHN, Andrew D.; MACINTYRE, Ciorsti; MACKALL, Judith A.; MONT, Lluis; NAPOLITANO, Carlo; OCHOA, Juan Pablo; PEICHL, Petr; PEREIRA, Alexandre C.; SCHWARTZ, Peter J.; SKINNER, Jon; STELLBRINK, Christoph; TFELT-HANSEN, Jacob; DENEKE, Thomas
  • article 436 Citação(ões) na Scopus
    2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy
    (2019) TOWBIN, Jeffrey A.; MCKENNA, William J.; ABRAMS, Dominic J.; ACKERMAN, Michael J.; CALKINS, Hugh; DARRIEUX, Francisco C. C.; DAUBERT, James P.; CHILLOU, Christian de; DEPASQUALE, Eugene C.; DESAI, Milind Y.; III, N. A. Mark Estes; HUA, Wei; INDIK, Julia H.; INGLES, Jodie; JAMES, Cynthia A.; JOHN, Roy M.; JUDGE, Daniel P.; KEEGAN, Roberto; KRAHN, Andrew D.; LINK, Mark S.; MARCUS, Frank I.; MCLEOD, Christopher J.; MESTRONI, Luisa; PRIORI, Silvia G.; SAFFITZ, Jeffrey E.; SANATANI, Shubhayan; SHIMIZU, Wataru; TINTELEN, J. Peter van; WILDE, Arthur A. M.; ZAREBA, Wojciech
    Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right/left ventricular cardiomyopathy, cardiac amyloidosis, sarcoidosis, Chagas disease, and left ventricular noncompaction. The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. This expert consensus statement provides the clinician with guidance on evaluation and management of ACM and includes clinically relevant information on genetics and disease mechanisms. PICO questions were utilized to evaluate contemporary evidence and provide clinical guidance related to exercise in arrhythmogenic right ventricular cardiomyopathy. Recommendations were developed and approved by an expert writing group, after a systematic literature search with evidence tables, and discussion of their own clinical experience, to present the current knowledge in the field. Each recommendation is presented using the Class of Recommendation and Level of Evidence system formulated by the American College of Cardiology and the American Heart Association and is accompanied by references and explanatory text to provide essential context. The ongoing recognition of the genetic basis of ACM provides the opportunity to examine the diverse triggers and potential common pathway for the development of disease and arrhythmia.
  • article 70 Citação(ões) na Scopus
    European Heart RhythmAssociation (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?
    (2018) DAGRES, Nikolaos; CHAO, Tze-Fan; FENELON, Guilherme; AGUINAGA, Luis; BENHAYON, Daniel; BENJAMIN, Emelia J.; BUNCH, T. Jared; CHEN, Lin Yee; CHEN, Shih-Ann; DARRIEUX, Francisco; PAOLA, Angelo de; FAUCHIER, Laurent; GOETTE, Andreas; KALMAN, Jonathan; KALRA, Lalit; KIM, Young-Hoon; LANE, Deirdre A.; LIP, Gregory Y. H.; LUBITZ, Steven A.; MARQUEZ, Manlio F.; POTPARA, Tatjana; POZZER, Domingo Luis; RUSKIN, Jeremy N.; SAVELIEVA, Irina; TEO, Wee Siong; TSE, Hung-Fat; VERMA, Atul; ZHANG, Shu; CHUNG, Mina K.; BAUTISTA-VARGAS, William-Fernando; CHIANG, Chern-En; CUESTA, Alejandro; DAN, Gheorghe-Andrei; FRANKEL, David S.; GUO, Yutao; HATALA, Robert; LEE, Young Soo; MURAKAWA, Yuji; PELLEGRINI, Cara N.; PINHO, Claudio; MILAN, David J.; MORIN, Daniel P.; NADALIN, Elenir; NTAIOS, George; PRABHU, Mukund A.; PROIETTI, Marco; RIVARD, Lena; VALENTINO, Mariana; SHANTSILA, Alena